18. Oncogene. 2018 Jul;37(29):4046-4054. doi: 10.1038/s41388-018-0235-y. Epub 2018Apr 26.Chronic expression of wild-type Ret receptor in the mammary gland induces luminaltumors that are sensitive to Ret inhibition.Gattelli A(1)(2)(3), García Solá ME(4)(5), Roloff TC(6), Cardiff RD(7), KordonEC(4)(5), Chodosh LA(8), Hynes NE(9)(10).Author information: (1)Universidad de Buenos Aires (UBA), Facultad de Ciencias Exactas y Naturales,Buenos Aires, Argentina. albanaga@fbmc.fcen.uba.ar.(2)CONICET-UBA, Instituto de Fisiología, Biología Molecular y Neurociencias(IFIBYNE), 1428 CABA, Buenos Aires, Argentina. albanaga@fbmc.fcen.uba.ar.(3)Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse66, CH-4058, Basel, Switzerland. albanaga@fbmc.fcen.uba.ar.(4)Universidad de Buenos Aires (UBA), Facultad de Ciencias Exactas y Naturales,Buenos Aires, Argentina.(5)CONICET-UBA, Instituto de Fisiología, Biología Molecular y Neurociencias(IFIBYNE), 1428 CABA, Buenos Aires, Argentina.(6)Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse66, CH-4058, Basel, Switzerland.(7)Pathology and Laboratory Medicine, Center for Genomic Pathology, School ofMedicine, University of California Davis (UCD), County Rd. 98 & Hutchison Dr,Davis, USA.(8)Department of Cancer Biology, Perelman School of Medicine, University ofPennsylvania (Upenn), 614 BRB II/III, 421 Curie Blvd, Philadelphia, USA.(9)Friedrich Miescher Institute for Biomedical Research (FMI), Maulbeerstrasse66, CH-4058, Basel, Switzerland. Nancy.Hynes@fmi.ch.(10)University of Basel, CH-4002, Basel, Switzerland. Nancy.Hynes@fmi.ch.The receptor tyrosine kinase Ret, a key gain-of-function mutated oncoprotein inthyroid carcinomas, has recently been implicated in other cancer types. While Retcopy number gains and mutations have been reported at low frequencies in breasttumors, we and others have reported that Ret is overexpressed in about 40% ofhuman tumors and this correlates with poor patient prognosis. Ret activationregulates numerous intracellular pathways related to proliferation andinflammation, but it is not known whether abnormal Ret expression is sufficientto induce mammary carcinomas. Using a novel doxycycline-inducible transgenicmouse model with the MMTV promoter controlling Ret expression, we show thatoverexpression of wild-type Ret in the mammary epithelium produces mammarytumors, displaying a morphology that recapitulates characteristics of humanluminal breast tumors. Ret-evoked tumors are estrogen receptor positive andnegative for progesterone receptor. Moreover, tumors rapidly regress afterdoxycycline withdrawal, indicating that Ret is the driving oncoprotein. Usingnext-generation sequencing, we examined the levels of transcripts in thesetumors, confirming a luminal signature. Ret-evoked tumors have been passaged inmice and used to test novel therapeutic approaches. Importantly, we havedetermined that tumors are resistant to endocrine therapy, but respondsuccessfully to treatment with a Ret kinase inhibitor. Our data provide the firstcompelling evidence for an oncogenic role of non-mutated Ret in the mammary glandand are an incentive for clinical development of Ret as a cancer biomarker andtherapeutic target.DOI: 10.1038/s41388-018-0235-y PMID: 29695833 